Business Context and Reporting Period
Company: OncoGenex Pharmaceuticals, Inc. (Note: Metadata listed "ACHIEVE LIFE SCIENCES, INC." but the filing text identifies OncoGenex Pharmaceuticals, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: February 11, 2015
Context: The Company entered into a new office lease and terminated its prior lease agreement, involving significant cash outflows for termination fees and potential contingent payments.
Key Financial Metrics and Obligations
- New Lease Costs: Monthly base rent starts at approximately $18,000 (May 1, 2015), increasing annually to approximately $20,000.
- New Lease Security: Obligation to deliver a $190,000 letter of credit.
- Termination Fee (Immediate): $2,000,000 payable to the prior landlord (BMR) by March 1, 2015.
- Termination Fee (Contingent): Additional $1,250,000 payable within 30 days of meeting Phase 3 clinical trial primary endpoints AND closing funding transactions of at least $20,000,000.
- Deferred Tax Liability: Approximately $80,000 to be drawn from the existing letter of credit for deferred state sales tax.
- Cost Avoidance: The termination avoids up to $6,700,000 in minimum rent payments over the remaining term of the old lease.
Material Changes Versus Prior Period
The filing does not provide comparative financial statements (revenue, profit, or cash flow) for the prior period. The material change is the restructuring of the Company's real estate footprint:
- Location Change: Moving from 1522 217th Place S.E. to 19820 North Creek Parkway, Bothell, WA.
- Space Reduction: New lease covers 11,526 sq. ft. (with an option for 8,054 sq. ft.), replacing the prior lease.
- Liquidity Impact: Immediate requirement to fund a $2,000,000 termination fee and a $190,000 letter of credit.
Outlook, Risks, and Contingencies
- Contingent Liability: The $1,250,000 additional termination fee is contingent on specific clinical trial success (Phase 3 for custirsen) and raising at least $20,000,000 in funding.
- Environmental Risk: The Company remains obligated to remediate any environmental conditions identified in a third-party audit of the old premises prior to the termination date.
- Lease Terms: The new lease expires April 30, 2018, with an option to extend for approximately three years.
- Default Risk: The $190,000 letter of credit for the new lease may be drawn upon for base rent or damages in the event of default.
Investor Verification Checklist
- Verify the Company's current cash position to ensure it can cover the immediate $2,000,000 termination fee and $190,000 letter of credit.
- Confirm the status of the Phase 3 clinical trial for custirsen to assess the likelihood of the $1,250,000 contingent payment.
- Review the Company's capital raise plans to determine if the $20,000,000 funding threshold for the contingent fee is achievable.
- Check for any environmental audit results regarding the terminated lease premises that could trigger remediation costs.